Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Mesenchymal stem cells (MSCs) exhibit complex immune-modulatory effects, presenting both antitumor and protumor potential in cancer treatment.
• MSCs are explored as delivery vehicles for gene and cell therapy, with genetic modification aiming to enhance their tumor-targeting and cancer-eliminating capabilities.
• Despite advancements, the efficacy of engineered MSCs in solid tumors remains constrained by factors including cell source, transgene choice, and tumor microenvironment interactions.

Purpose of the Study:

• To review the progress of gene and cell therapy utilizing mesenchymal stem cells (MSCs) as a core strategy against solid tumors.
• To address various MSC engineering methods developed over decades of research.
• To summarize the therapeutic objectives of engineered MSCs for common cancers and discuss associated challenges and benefits.

Main Methods:

• Review of existing literature on mesenchymal stem cell (MSC) based gene and cell therapy for solid tumors.
• Analysis of different MSC engineering techniques and their outcomes.
• Discussion of challenges, limitations, risks, and advantages of engineered MSCs in combination with conventional cancer therapies.

Main Results:

• Mesenchymal stem cells (MSCs) can be engineered to enhance their antitumor effects, acting as targeted delivery systems for gene and cell therapies.
• Various genetic modification strategies have been employed to improve MSC efficacy against solid tumors.
• The effectiveness of engineered MSCs is influenced by the specific cancer type, the genetic modifications, and the tumor microenvironment.

Conclusions:

• Engineered mesenchymal stem cells (MSCs) represent a promising frontier in combined gene and cell therapy for solid tumors.
• Further research into MSC engineering methods and understanding tumor-specific interactions is crucial for optimizing therapeutic outcomes.
• Addressing the challenges and risks associated with engineered MSCs is essential for their successful clinical translation in cancer treatment.